Hema Majeno, PA

Hema Majeno practices at Fresno Ambulatory Surgery Center in Fresno, California.

Hema Majeno's NPI, 1437552478, was assigned on October 5, 2014. Hema Majeno holds California license 52025.

Hema Majeno's primary practice is Fresno Ambulatory Surgery Center, at 568 E Herndon Ave, Fresno, CA 93720. The practice phone is (559) 431-0066.

Hema Majeno's primary practice is Fresno Ambulatory Surgery Center in Fresno, California. Hema Majeno is also affiliated with Dignity Health - Mercy Medical Center. The medical group on file is San Joaquin Emergency Medical Associates. Dmand AI also links Hema Majeno to 2 more home health agencies, 2 medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Hema Majeno practices, 5 sites in all. Vendor and product names are available with a free account.

Medical is Hema Majeno's primary specialty in the NPI Registry, under taxonomy code 363AM0700X. Hema Majeno is board certified in certified physician assistant by the National Commission on Certification of Physician Assistants (NCCPA). Hema Majeno is licensed in California.

CMS data shows 545 Medicare services from Hema Majeno across 4 procedure codes in 2024, for 232 Medicare patients. Medicare paid $40,303 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 232 Medicare patients who saw Hema Majeno in 2024. The largest group is 65 to 74, with 73 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 57% are also on Medicaid. Their average risk score is 2.83, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Hema Majeno's median patient age at 71, with 57% women.

In 2024, Hema Majeno wrote 195 Medicare Part D claims for 85 patients. 85% of them were for generic drugs. CMS names the drug for 36 of them, across 3 drugs with 11 or more claims each, at $160 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Hema Majeno for performance year 2024, reported as part of a group. Hema Majeno accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Hema Majeno as offering telehealth.

CMS Open Payments shows 2 general payments to Hema Majeno from 2 drug and device companies in 2025. Food and beverage make up the largest share, 100% of the total. AstraZeneca Pharmaceuticals LP paid the most, $111.